This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.


This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.


This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

About Sogroya®


Sogroya® is a once-weekly growth hormone therapy for your paediatric patients with growth hormone deficiency.1

Device and dosing

With Sogroya® your patients get simple and flexible dosing using an easy, familiar and ready-to-use device for their treatment.1-3
Efficacy and safety


Treatment with Sogroya® provides efficacy, an IGF-1 response and a safety profile that is comparable to once-daily GH treatment.1


Sogroya® Summary of Product Characteristics. 2022:1-92.


Norditropin® FlexPro® Summary of Product Characteristics. 2021:1-65.


Miller BS JC Rasmussen MH, et al. Weekly Somapacitan is Effective and Well Tolerated In children With GH Deficiency: The Randomised Phase 3 REAL4 Trial. J Clin Endocrinol Metab. 022:00(0):1-11.